Case Report: Excellent Response to Long-Term Higher Dose Single Olanzapine in a Case of Recurrent Brief Depression

Abbreviations

ACTH

adrenocorticotropic hormone, corticotropin

BPD

borderline personality disorder

DIB

diagnostic interview for borderlines

DSM

Diagnostic and Statistical Manual of Mental Disorders

HDRS-17

Hamilton depression rating scale of 17 items

ICD

international classification of diseases

MD

major depression

OLZ

olanzapine

RBD

recurrent brief depression

SADS-L

the schedule for affective disorders and schizophrenia, lifetime version

T3

triiodothyronine

T4

tetraiodothyronine, thyroxine

TSH

thyroid-stimulating hormone

References

• 1 American Psychiatric Association . Diagnostic and statistical manual of mental disorders. 4th Edition. Washington, DC: American Psychiatric Association 1994
• 2 Angst J, Merinkangas K, Scheidegger P, Wicki W. Recurrent brief depression: a new subtype of affective disorder.  J Affective Disorders. 1990;  19 87-98
• 3 Angst J, Sellaro R, Merikangas K. Depressive Spectrum Diagnoses.  Comprehensive Psychiatry. 200;  41 39-47
• 4 Assion HJ, Jungck C. Off-label prescribing in a German psychiatric hospital.  Pharmacopsychiatry. 2007;  40 30-36
• 5 Earley W, Mitchel M, Marquez E, Kurtz D, Falk D, Taylor CC, Cavazzoni P. Preliminary pharmacokinetics and tolerability of higher dose olanzapine. Presented at the 157th annual meeting of the American Psychiatric Association. New York, NY May 1–6, 2004
• 6 Endicott J, Spitzer RL. A diagnostic interview: the schedule for affective disorders and schizophrenia.  Arch Gen Psychiatry. 1978;  35 837-444
• 7 Glazer WM. Olanzapine and the new generation of antipsychotic agents: patterns of use.  J Clin Psychiatr. 1997;  58 18-21
• 8 Gunderson JG, Kolb JE, Austin V. The diagnostic interview for borderline patients (DIB).  Am J Psychiatr. 1981;  138 896-903
• 9 Herings RM, Erkens JA. Increased suicide attempt rate among patients interrupting use of atypical antipsychotics.  Pharmacoepidemiology Drug Safety. 2003;  12 423-424
• 10 Jackson WC, Manning JS, Connor PD, Deardorff OG. Retrospective study of olanzapine in depressive and anxious states primary care. Primary care companion.  J Clin Psychiatr. 2004;  6 199-202
• 11 Jarema M. Atypical antipsychotics in the treatment of mood disorders.  Current Opinion in Psychiatry. 2007;  20 23-29
• 12 Karow A, Schnedler D, Naber D. What would the patient choose? Subjective comparison of atypical and typical neuroleptics.  Pharmacopsychiatry. 2006;  39 47-51
• 13 Keck Jr PE, Strakowski SM, MacElroy SL. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia.  J Clin Psychiatr. 2000;  61 4-9
• 14 Nemeroff CB. Use of atypical antipsychotics in refractory depression and anxiety.  J Clinical Psychiatr. 2006;  66 13-21
• 15 Pezawas L, Angst J, Kasper S. Recurrent brief depression revisited.  Int Rev Psychiatry. 2005;  17 63-70
• 16 World Health Organization . The ICD-10 Classification of Mental and BehaviouraI Disorders, Clinical Descriptions and Diagnostic Guidelines. WHO. Geneva 1992

Correspondence